{"id":"melphalan-prednisolone","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"20-40","effect":"Infection"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"10-30","effect":"Mucositis"},{"rate":"5-10","effect":"Secondary malignancy"},{"rate":"20-30","effect":"Hyperglycemia (prednisolone-related)"},{"rate":"variable","effect":"Immunosuppression complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Melphalan is a nitrogen mustard derivative that cross-links DNA strands, preventing cell division and inducing apoptosis in rapidly dividing cells. Prednisolone enhances the cytotoxic effect and provides immunosuppression and anti-inflammatory benefits. This combination is commonly used in multiple myeloma treatment protocols.","oneSentence":"Melphalan is an alkylating agent that damages DNA, while prednisolone is a corticosteroid that suppresses immune function; together they work to kill cancer cells and reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:37.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Light chain deposition disease"}]},"trialDetails":[{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT04151615","phase":"","title":"VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-11-15","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT00745420","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT01998633","phase":"PHASE2","title":"Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2013-12","conditions":"Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease","enrollment":47},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT02500550","phase":"PHASE2","title":"Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor","status":"COMPLETED","sponsor":"Kiadis Pharma","startDate":"2015-10-09","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT00582816","phase":"PHASE1, PHASE2","title":"Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2008-08","conditions":"Leukemia, Solid Tumors","enrollment":9},{"nctId":"NCT00550992","phase":"NA","title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","status":"UNKNOWN","sponsor":"Dutch Childhood Oncology Group","startDate":"2006-01","conditions":"Leukemia","enrollment":445},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT00002835","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1995-10-30","conditions":"Lymphoma","enrollment":116},{"nctId":"NCT01745913","phase":"PHASE2","title":"Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-26","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT02199041","phase":"PHASE2","title":"Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-07-11","conditions":"Hematological Malignancies","enrollment":24},{"nctId":"NCT00290628","phase":"NA","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1999-10","conditions":"Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia","enrollment":43},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":"Lymphoma","enrollment":442},{"nctId":"NCT00317408","phase":"NA","title":"Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma","status":"UNKNOWN","sponsor":"European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma","startDate":"2004-04","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT00084695","phase":"PHASE2","title":"Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases","status":"UNKNOWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2003-09","conditions":"Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia","enrollment":25},{"nctId":"NCT00008307","phase":"PHASE2","title":"Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"1998-04","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":52},{"nctId":"NCT00002599","phase":"PHASE3","title":"Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1994-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":750},{"nctId":"NCT00436761","phase":"PHASE1","title":"Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors","status":"UNKNOWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2004-05","conditions":"Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":20},{"nctId":"NCT00985959","phase":"PHASE1","title":"A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT00205764","phase":"PHASE3","title":"Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy","status":"COMPLETED","sponsor":"Austrian Forum Against Cancer","startDate":"1999-03","conditions":"Multiple Myeloma","enrollment":212},{"nctId":"NCT00003603","phase":"PHASE3","title":"Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Riverside Haematology Group","startDate":"1998-03","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":660},{"nctId":"NCT00003815","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Scotland and Newcastle Lymphoma Group","startDate":"1994-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00669812","phase":"PHASE2","title":"High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma","status":"UNKNOWN","sponsor":"Cancer Research UK","startDate":"2008-02","conditions":"Lymphoma, Small Intestine Cancer","enrollment":60},{"nctId":"NCT00934154","phase":"PHASE3","title":"Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Cigdem Sahinbas YILMAZ","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":122},{"nctId":"NCT00025064","phase":"PHASE2","title":"Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2000-01","conditions":"Lymphoma","enrollment":260},{"nctId":"NCT00112645","phase":"PHASE1","title":"Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2005-04","conditions":"Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":10},{"nctId":"NCT00003215","phase":"PHASE3","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1997-04","conditions":"Lymphoma","enrollment":400},{"nctId":"NCT00003335","phase":"PHASE2","title":"Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1998-01","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":44},{"nctId":"NCT00055653","phase":"PHASE2","title":"Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2003-01","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00003662","phase":"PHASE2","title":"Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1998-08","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":90},{"nctId":"NCT00003661","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1998-06","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":3},{"nctId":"NCT00003336","phase":"PHASE2","title":"Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1998-01","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases","enrollment":6},{"nctId":"NCT00558220","phase":"PHASE2","title":"R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Czech Lymphoma Study Group","startDate":"2002-05","conditions":"Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma, Follicular Lymphoma Grade III","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Melphalan+Prednisolone","genericName":"Melphalan+Prednisolone","companyName":"Cigdem Sahinbas YILMAZ","companyId":"cigdem-sahinbas-yilmaz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Melphalan is an alkylating agent that damages DNA, while prednisolone is a corticosteroid that suppresses immune function; together they work to kill cancer cells and reduce inflammation. Used for Multiple myeloma, Light chain deposition disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}